ConvaTec Group PLC (LON:CTEC) Given Average Rating of “Buy” by Brokerages

Shares of ConvaTec Group PLC (LON:CTEC) have earned an average rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is GBX 318.67.

Several research firms have commented on CTEC. Peel Hunt reaffirmed an “add” rating and set a GBX 270 price objective on shares of ConvaTec Group in a research note on Thursday, November 13th. UBS Group restated a “buy” rating and issued a GBX 375 target price on shares of ConvaTec Group in a report on Friday, November 7th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of ConvaTec Group in a research note on Friday, November 14th.

ConvaTec Group Stock Performance

LON CTEC opened at GBX 238 on Friday. The business’s 50 day moving average price is GBX 237.52 and its 200-day moving average price is GBX 243.89. ConvaTec Group has a fifty-two week low of GBX 218 and a fifty-two week high of GBX 311.20. The company has a market cap of £4.65 billion, a P/E ratio of 22.45, a P/E/G ratio of 0.93 and a beta of 0.64. The company has a debt-to-equity ratio of 85.32, a quick ratio of 0.96 and a current ratio of 2.26.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.